Mouse models of blood pressure regulation and hypertension

Current Hypertension Reports

Volumn 3, Issue 1, 2001, Pages 41-48

  Sugiyama, Fumihiro ^a   Yagami, Ken Ichi ^a   Paigen, Beverly ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANIMAL MODEL; BLOOD PRESSURE; DISEASE MODEL; GENETICS; HUMAN; HYPERTENSION; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; MICE; MODELS, ANIMAL;

EID: 0035256894     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0077-8     Document Type: Article

References (71)

1. Ohkubo H, Kawakami H, Kakehi Y, et al.: Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci U S A 1990, 87: 5153-5157.
2. Fukamizu A, Sugimura K, Takimoto E, et al.: Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem 1993, 268: 11617-11621.
3. Merrill DC, Thompson MW, Carney CL, et al.: Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest 1996, 97: 1047-1055.
4. Sugiyama F, Haraoka S, Watanabe T, et al.: Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab Invest 1997, 76: 835-842.
5. Nishijo N, Sugiyama F, Kimoto K, et al.: Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Lab Invest 1998, 78: 1059-1066.
6. Takimoto E, Ishida J, Sugiyama F, et al.: Hypertension induced in pregnant mice by placental renin and maternal angiotensinogen. Science 1996, 274: 995-998.
7. Tanimoto K, Sugiyama F, Goto Y, et al.: Angiotensinogendeficient mice with hypotension. J Biol Chem 1994, 269: 31334-31337.
8. Kim HS, Krege JH, Kluckman KD, et al.: Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A 1995, 92: 2735-2739.
9. Niimura F, Labosky PA, Kakuchi J, et al.: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995, 96: 2947-2954.
10. Davisson RL, Kim HS, Krege JH, et al.: Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J Clin Invest 1997, 99: 1258-1264.
11. Ishida J, Sugiyama F, Tanimoto K, et al.: Rescue of angiotensinogen- knockout mice. Biochem Biophys Res Commun 1998, 252: 610-616.
12. Taniguchi K, Sugiyama F, Kakinuma Y, et al.: Pathologic characterization of hypotensive C57BL/6J-agt: angiotensinogen-deficient C57BL/6J mice. Int J Mol Med 1998, 1: 583-587.
13. Sugiyama F, Tanimoto Y, Kato H, et al.: Speedy backcrossing through in vitro fertilization, using prepubertal superovulation and neonatal death dependent on genetic background in angiotensinogen-deficient mice. Lab Anim Sci 1997, 47: 545-548.
14. Kakinuma Y, Hama H, Sugiyama F, et al.: Impaired bloodbrain barrier function in angiotensinogen-deficient mice. Nat Med 1998, 4: 1078-1080.
15. Ito M, Oliverio MI, Mannon PJ, et al.: Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci U S A 1995, 92: 3521-3525.
16. Sugaya T, Nishimatsu S, Tanimoto K, et al.: Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995, 270: 18719-18722.
17. Oliverio MI, Best CF, Kim HS, et al.: Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation. Am J Physiol 1997, 272: F515-F520.
18. Chen X, Li W, Yoshida H, et al.: Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 1997, 272: F299-F304.
19. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD: Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest 2000, 106: 103-106.
20. Tsuchida S, Matsusaka T, Chen X, et al.: Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998, 101: 755-760.
21. Oliverio MI, Kim HS, Ito M, et al.: Reduced growth, abnormal kidney structure, and type 2(AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc Natl Acad Sci U S A 1998, 95: 15496-15501.
22. Ichiki T, Labosky PA, Shiota C, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377: 748-750.
23. Hein L, Barsh GS, Pratt RE, et al.: Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995, 377: 744-747.
24. Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci U S A 1999, 96: 6506-6510.
25. Tsutsumi Y, Matsubara H, Masaki H, et al.: Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999, 104: 925-935.
26. Yanai K, Saito T, Kakinuma Y, et al.: Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J Biol Chem 2000, 275: 5-8.
27. Huang PL, Dawson TM, Bredt DS, et al.: Targeted disruption of the neuronal nitric oxide synthase gene. Cell 1993, 75: 1273-1286.
28. Shesely EG, Maeda N, Kim HS, et al.: Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1996, 93: 13176-13181.
29. Abe H, Yamada N, Kamata K, et al.: Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998, 101: 1784-1788.
30. Steinhelper ME, Cochrane KL, Field LJ: Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990, 16: 301-307.
31. Ogawa Y, Itoh H, Tamura N, et al.: Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 1994, 93: 1911-1921.
32. John SW, Krege JH, Oliver PM, et al.: Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267: 679-681.
33. Lopez MJ, Wong SK, Kishimoto I, et al.: Salt-resistant hypertension in mice lacking the guanylyl cyclase A receptor for atrial natriuretic peptide. Nature 1995, 378: 65-68.
34. Oliver PM, Fox JE, Kim R, et al.: Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci U S A 1997, 94: 14730-14735.
35. Tamura N, Ogawa Y, Chusho H, et al.: Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A 2000, 97: 4239-4244.
36. Matsukawa N, Grzesik WJ, Takahashi N, et al.: The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci U S A 1999, 96: 7403-7408.
37. Jaubert J, Jaubert F, Martin N, et al.: Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci U S A 1999, 96: 10278-10283.
38. Kennedy CR, Zhang Y, Brandon S, et al.: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999, 5: 217-220.
39. Tilley SL, Audoly LP, Hicks EH, et al.: Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. J Clin Invest 1999, 103: 1539-1545.
40. Audoly LP, Nguyen M, Koller BH, Coffman TM: The prostaglandin EP4 receptor subtype is an essential component of blood pressure regulation in males, but not females [abstract]. FASEB J 1999, 13: A1549.
41. Audoly LP, Kim H, Flannery PJ, et al.: Mice lacking the prostaglandin E2 EP1 receptor subtype have hypotension, hyperenimia, and altered responses to angiotensin II [abstract]. FASEB J 1999, 13: A1549.
42. Cho MC, Rao M, Koch WJ, et al.: Enhanced contractility and decreased beta adrenergic receptor kinase 1 in mice lacking endogenous norepinephrine and epinephrine. Circulation 1999, 99: 2702-2707.
43. Gavras H, Handy D, Gavras I: Alpha adrenergic receptors in hypertension. In Hypertension: Pathophysiology, Diagnosis, and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press, Ltd.; 1995: 853-861.
44. Cavalli A, Lattion AL, Hummler E, et al.: Decreased blood pressure response in mice deficient of the alpha1b adrenergic receptor. Proc Natl Acad Sci U S A 1997, 94: 11589-11594.
45. Milano CA, Dolber PC, Rockman HA, et al.: Myocardial expression of a constitutively active a 1B adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A 1994, 91: 10109-10113.
46. Link RE, Stevens MS, Kulatunga M, et al.: Targeted inactivation of the gene encoding the mouse alpha 2c adrenoceptor homolog. Mol Pharmacol 1995, 48: 48-55.
47. MacMillan LB, Hein L, Smith MS, et al.: Central hypotensive effects of the alpha2a adrenergic receptor subtype. Science 1996, 273: 801-803.
48. Link RE, Desai K, Hein L, et al.: Cardiovascular regulation in mice lacking alpha2 adrenergic receptor subtypes b and c. Science 1996, 273: 803-805.
49. Altman JD, Trendelenburg AU, MacMillan L, et al.: Abnormal regulation of the sympathetic nervous system in alpha2A adrenergic receptor knockout mice. Mol Pharmacol 1999, 56: 154-161.
50. Makaritsis KP, Johns C, Gavras I, et al.: Sympathoinhibitory function of the a 2A adrenergic receptor subtype. Hypertension 1999, 34: 403-407.
51. Duka I, Gavras I, Johns C, et al.: Role of the postsynaptic a 2 adrenergic receptor subtypes in catecholamine induced vasoconstriction. Gen Pharmacol 2000, 34: 101-106.
52. Makaritsis KP, Johns C, Gavras I, Gavras H: Role of a 2 adrenergic receptor subtypes in the acute hypertensive response to hypertonic saline infusion in anephric mice. Hypertension 2000, 35: 609-613.
53. Makaritsis KP, Handy DE, Johns C, et al.: Role of the a 2B adrenergic receptor in the development of salt induced hypertension. Hypertension 1999, 33: 14-17.
54. Handy DE, Johns C, Bresnahan MR, et al.: Expression of a 2 adrenergic receptors in normal and atherosclerotic rabbit aorta. Hypertension 1998, 32: 311-317.
55. Ping P, Faber JE: Characterization of alpha adrenoceptor gene expression in arterial and venous smooth muscle. Am J Physiol 1993, 265: H1501-H1509.
56. Rohrer DK, Desai KH, Jasper JR, et al.: Targeted disruption of the mouse beta1 adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci U S A 1996, 93: 7375-7380.
57. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in beta1 adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96: 7059-7064.
58. Chruscinski AJ, Rohrer DK, Schauble E, et al.: Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999, 274: 16694-16700.
59. Cross HR, Steenbergen C, Lefkowitz RJ, et al.: Overexpression of the cardiac beta (2) adrenergic receptor and expression of a beta adrenergic receptor kinase 1(betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res 1999, 85: 1077-1084.
60. Dorn GW II, Tepe NM, Lorenz JN, et al.: Low- and high level transgenic expression of beta2 adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq overexpressing mice. Proc Natl Acad Sci U S A 1999, 96: 6400-6405.
61. Turki J, Lorenz JN, Green SA, et al.: Myocardial signaling defects and impaired cardiac function of a human beta 2 adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 1996, 93: 10483-10488.
62. Susulic VS, Frederich RC, Lawitts J, et al.: Targeted disruption of the beta 3 adrenergic receptor gene. J Biol Chem 1995, 270: 29483-29492.
63. Albrecht FE, Drago J, Felder RA, et al.: Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 1996, 97: 2283-2288.
64. Asico LD, Ladines C, Fuchs S, et al.: Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J Clin Invest 1998, 10 2: 493-498.
65. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al.: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000, 105: 1243-1252.
66. Rapp JP: Genetic analysis of inherited hypertension in the rat. Physiol Rev 2000, 80: 135-172.
67. Stoll M, Kwitek-Black AE, Cowley Jr AW, et al.: New target regions for human hypertension via comparative genomics. Genome Res 2000, 10: 473-482.
68. Wright FA, O'Connor DT, Roberts E, et al.: Genome scan for blood pressure loci in mice. Hypertension 1999, 34: 625-630.
69. Sugiyama H, Churchill GA, Higgins DC, et al.: Concordance of murine quantitative trait loci for salt-induced hypertension with rat and human loci. Genomics 2000, in press.
70. Nolan PM, Peters J, Strivens M, et al.: A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet 2000, 25: 440-443.
71. Hrabe De Angelis MH, Flaswinkel H, Fuchs H, et al.: Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet 2000, 25: 444-447.